Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
0.3980
+0.0079 (2.03%)
At close: Nov 6, 2026, 4:00 PM EST
0.3993
+0.0013 (0.33%)
After-hours: Nov 6, 2026, 7:17 PM EST
Lucid Diagnostics Revenue
Lucid Diagnostics had revenue of $1.47M in the quarter ending June 30, 2026, with 26.74% growth. This brings the company's total for the last twelve months to $5.45M, up 24.89% year-over-year. In the year 2025, Lucid Diagnostics had annual revenue of $4.71M with 8.28% growth. That makes Lucid Diagnostics the 39,713th largest company in the world by revenue and 5,257th in the United States.
Revenue (ttm)
$5.45M
Revenue Growth
+24.89%
P/S Ratio
13.96
Revenue / Employee
$66,402
Employees
82
Market Cap
76.00M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.71M | 360.00K | 8.28% |
| Dec 31, 2024 | 4.35M | 1.92M | 79.00% |
| Dec 31, 2023 | 2.43M | 2.05M | 544.03% |
| Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Outset Medical | 121.97M |
| Pulmonx | 88.78M |
| LENSAR | 60.26M |
| electroCore | 37.97M |
| Nyxoah | 32.77M |
| Hyperfine | 16.54M |
| Spectral AI | 15.39M |
| Perspective Therapeutics | 409.00K |
LUCD News
- 2 days ago - Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year - PRNewsWire
- 3 days ago - Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PRNewsWire
- 4 days ago - Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study - PRNewsWire
- 8 days ago - PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 - PRNewsWire
- 9 days ago - Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 - PRNewsWire
- 16 days ago - Lucid Diagnostics begins receiving Medicare reimbursement for EsoGuard - TheFly
- 16 days ago - Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing - PRNewsWire
- 5 weeks ago - Needham sees no reason for Lucid Diagnostics selloff today - TheFly